{
  "drug_id": "D004",
  "drug_name": "Dermavax",
  "indication": "Autoimmune-A",
  "modality": "bispecific antibody",
  "mechanism": "targeted receptor antagonist",
  "moa_short": "Blocks receptor-mediated signaling to reduce disease activity.",
  "formulation": "prefilled syringe",
  "route": "subcutaneous",
  "regimen": "100 mg QW",
  "trial_id": "AMGN-D004-302",
  "phase": "Phase 3",
  "arms": [
    {
      "name": "Dermavax 100 mg QW",
      "n": 255,
      "dose": "100 mg QW"
    },
    {
      "name": "Placebo",
      "n": 254,
      "dose": "matching regimen"
    }
  ],
  "population": "Adults with moderate-to-severe Autoimmune-A with inadequate response to standard therapy.",
  "key_inclusion": [
    "Confirmed diagnosis per protocol definition",
    "Baseline disease activity above threshold",
    "Stable background therapy for \u22654 weeks"
  ],
  "key_exclusion": [
    "Severe uncontrolled comorbidity (per protocol)",
    "Recent major surgery within 12 weeks",
    "Known hypersensitivity to components"
  ],
  "results": {
    "endpoint_primary": "Change from baseline in Symptom Score at Week 12",
    "endpoint_secondary": "Time to flare through Week 24",
    "primary_effect": "LS mean difference -1.00 (Drug \u2212 Placebo)",
    "primary_pvalue": 0.048974205196812705,
    "primary_ci": "[-1.40, -0.60]",
    "secondary_effect": "Did not meet prespecified significance threshold",
    "discontinuation_rate_pct": 8.894698173446958
  },
  "safety": {
    "common_ae": [
      [
        "Upper respiratory infection",
        6.16450023031658
      ],
      [
        "Fatigue",
        5.399856701008002
      ],
      [
        "Nausea",
        4.000228732334217
      ],
      [
        "Elevated ALT",
        2.914589879895847
      ],
      [
        "Injection-site reaction",
        2.0
      ],
      [
        "Arthralgia",
        2.0
      ]
    ],
    "serious_ae_rate_pct": 1.6684771839890113,
    "discontinuation_ae_rate_pct": 2.2612887827853863,
    "warnings": [
      "Monitor for hypersensitivity reactions.",
      "Assess for infection risk in susceptible patients.",
      "Consider hepatic monitoring if clinically indicated."
    ],
    "contraindications": [
      "Known hypersensitivity to active substance or excipients."
    ]
  },
  "monitoring": [
    "Baseline labs per protocol (CBC, CMP)",
    "Periodic assessment of liver enzymes",
    "Clinical monitoring for infections"
  ],
  "version": "v2.9",
  "doc_date": "2025-12-26"
}